vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Priority Technology Holdings, Inc.（PRTH）财务数据对比。点击上方公司名可切换其他公司
Priority Technology Holdings, Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.6倍（$247.1M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 3.6%，领先30.9%），Priority Technology Holdings, Inc.同比增速更快（8.8% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $30.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 9.6%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Priority Technology Holdings, Inc.是一家聚焦信息技术领域的企业，业务围绕计算机、通信系统等相关信息设备展开，涵盖信息的创建、处理、存储、检索与传输等相关信息技术应用服务，依托计算机科学与工程技术支撑业务开展。
CPRX vs PRTH — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $247.1M |
| 净利润 | $52.7M | $8.9M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 13.6% |
| 净利率 | 34.5% | 3.6% |
| 营收同比 | 7.6% | 8.8% |
| 净利润同比 | -5.8% | 23.9% |
| 每股收益（稀释后） | $0.40 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $247.1M | ||
| Q3 25 | $148.4M | $241.4M | ||
| Q2 25 | $146.6M | $239.8M | ||
| Q1 25 | $141.4M | $224.6M | ||
| Q4 24 | $141.8M | $227.1M | ||
| Q3 24 | $128.7M | $227.0M | ||
| Q2 24 | $122.7M | $219.9M | ||
| Q1 24 | $98.5M | $205.7M |
| Q4 25 | $52.7M | $8.9M | ||
| Q3 25 | $52.8M | $27.6M | ||
| Q2 25 | $52.1M | $10.9M | ||
| Q1 25 | $56.7M | $8.3M | ||
| Q4 24 | $55.9M | $7.2M | ||
| Q3 24 | $43.9M | $10.6M | ||
| Q2 24 | $40.8M | $994.0K | ||
| Q1 24 | $23.3M | $5.2M |
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
| Q4 25 | 40.5% | 13.6% | ||
| Q3 25 | 44.7% | 15.6% | ||
| Q2 25 | 45.2% | 15.6% | ||
| Q1 25 | 44.8% | 14.5% | ||
| Q4 24 | 44.3% | 15.0% | ||
| Q3 24 | 39.6% | 16.8% | ||
| Q2 24 | 44.2% | 15.1% | ||
| Q1 24 | 27.5% | 13.6% |
| Q4 25 | 34.5% | 3.6% | ||
| Q3 25 | 35.6% | 11.4% | ||
| Q2 25 | 35.6% | 4.5% | ||
| Q1 25 | 40.1% | 3.7% | ||
| Q4 24 | 39.4% | 3.2% | ||
| Q3 24 | 34.1% | 4.7% | ||
| Q2 24 | 33.2% | 0.5% | ||
| Q1 24 | 23.6% | 2.5% |
| Q4 25 | $0.40 | $0.10 | ||
| Q3 25 | $0.42 | $0.34 | ||
| Q2 25 | $0.41 | $0.14 | ||
| Q1 25 | $0.45 | $0.10 | ||
| Q4 24 | $0.44 | $-0.05 | ||
| Q3 24 | $0.35 | $0.07 | ||
| Q2 24 | $0.33 | $-0.23 | ||
| Q1 24 | $0.19 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $77.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $954.3M | $-100.4M |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $77.2M | ||
| Q3 25 | $689.9M | $57.0M | ||
| Q2 25 | $652.8M | $50.6M | ||
| Q1 25 | $580.7M | $47.6M | ||
| Q4 24 | $517.6M | $58.6M | ||
| Q3 24 | $442.3M | $41.1M | ||
| Q2 24 | $375.7M | $34.6M | ||
| Q1 24 | $310.4M | $34.3M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $997.5M | ||
| Q2 25 | — | $917.0M | ||
| Q1 25 | — | $918.9M | ||
| Q4 24 | — | $920.9M | ||
| Q3 24 | — | $808.1M | ||
| Q2 24 | — | $809.0M | ||
| Q1 24 | — | $631.4M |
| Q4 25 | $954.3M | $-100.4M | ||
| Q3 25 | $920.2M | $-110.3M | ||
| Q2 25 | $856.0M | $-146.1M | ||
| Q1 25 | $794.3M | $-158.3M | ||
| Q4 24 | $727.6M | $-166.8M | ||
| Q3 24 | $660.9M | $-165.8M | ||
| Q2 24 | $608.7M | $-172.1M | ||
| Q1 24 | $561.4M | $-159.9M |
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $971.9M | $2.0B | ||
| Q1 25 | $908.9M | $1.9B | ||
| Q4 24 | $851.4M | $1.8B | ||
| Q3 24 | $772.0M | $1.8B | ||
| Q2 24 | $706.4M | $1.7B | ||
| Q1 24 | $646.7M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $36.8M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $30.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 12.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.4% |
| 现金转化率经营现金流/净利润 | 0.85× | 4.12× |
| 过去12个月自由现金流最近4个季度 | — | $75.1M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $36.8M | ||
| Q3 25 | $32.4M | $36.1M | ||
| Q2 25 | $71.3M | $17.1M | ||
| Q1 25 | $60.0M | $10.0M | ||
| Q4 24 | $70.9M | $23.8M | ||
| Q3 24 | $72.9M | $19.8M | ||
| Q2 24 | $64.1M | $28.7M | ||
| Q1 24 | $31.9M | $13.3M |
| Q4 25 | $44.9M | $30.9M | ||
| Q3 25 | — | $30.1M | ||
| Q2 25 | $71.3M | $9.2M | ||
| Q1 25 | — | $4.9M | ||
| Q4 24 | $70.8M | $19.1M | ||
| Q3 24 | $72.6M | $14.5M | ||
| Q2 24 | $64.1M | $23.6M | ||
| Q1 24 | $31.7M | $6.7M |
| Q4 25 | 29.4% | 12.5% | ||
| Q3 25 | — | 12.5% | ||
| Q2 25 | 48.6% | 3.8% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 49.9% | 8.4% | ||
| Q3 24 | 56.4% | 6.4% | ||
| Q2 24 | 52.3% | 10.7% | ||
| Q1 24 | 32.2% | 3.3% |
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.0% | 2.5% | ||
| Q2 25 | 0.0% | 3.3% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.1% | 2.0% | ||
| Q3 24 | 0.2% | 2.3% | ||
| Q2 24 | 0.0% | 2.3% | ||
| Q1 24 | 0.2% | 3.2% |
| Q4 25 | 0.85× | 4.12× | ||
| Q3 25 | 0.61× | 1.31× | ||
| Q2 25 | 1.37× | 1.57× | ||
| Q1 25 | 1.06× | 1.20× | ||
| Q4 24 | 1.27× | 3.29× | ||
| Q3 24 | 1.66× | 1.87× | ||
| Q2 24 | 1.57× | 28.87× | ||
| Q1 24 | 1.37× | 2.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
PRTH
暂无分部数据
